Navigation Links
Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia

A new study is providing scientists with a better understanding of why some pediatric acute lymphoblastic leukemia (ALL) patients fail to respond to treatment even when existing clinical predictive criteria point towards a positive treatment outcome. The research, published in the April issue of Cancer Cell, is likely to facilitate development of new strategies to combat drug resistance and treatment failure for children with ALL.

Nearly 80% of children with ALL are cured following chemotherapeutic treatment. However, the remaining 20% often exhibit drug resistance and treatment failure that is poorly understood. In some cases, patients are resistant to multiple drugs that have very little structural similarity, suggesting that the mechanisms for drug cross-resistance are probably not the same as mechanisms underlying resistance to a single drug. Dr. William E. Evans from St. Jude Children's Research Hospital and colleagues used a comprehensive genetic screening technique to search for genes that are differentially expressed in ALL cells that demonstrated cross-resistance to two or more commonly used chemotherapeutic agents.

The researchers identified several genes that were differentially expressed in ALL cells that exhibited de novo cross resistance to four widely used antileukemic agents. They went on to investigate the relationship of these genes to treatment outcome in ALL patients and found that expression of the genes was associated with treatment outcome and could be used to identify a subset of patients with a markedly inferior response to treatment. In addition, the findings revealed a previously unrecognized phenotype characterized by discordant resistance to two widely used and mechanistically distinct antileukemic agents and provided new information about the cellular mechanisms involved in disparate response to these drugs.

Specific genetic signatures related to ALL treatment failure and chemotherapeutic cross-resistance were mor e effective at identifying select populations of patients with inferior treatment outcomes than expression patterns associated with resistance to a single drug. "These findings provide new insights into the biological basis of de novo multiple-drug resistance and illuminate potential new targets for overcoming this cause of treatment failure in childhood ALL," explains Dr. Evans.


'"/>

Source:Cell Press


Related biology news :

1. NYCs First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention
2. Drug-resistant bacteria on poultry products differ by brand
3. Genetic discovery could lead to drought-resistant plants
4. UF researchers kill resistant bugs one bandage at a time
5. DDT-resistant insects have additional genetic advantage that helps resistance spread
6. Drug resistant avian influenza viruses more common in Southeast Asia than North America
7. New molecule may aid in production of biofuels and fungi-resistant plants
8. Reducing antibiotic use lowers rates of drug-resistant bacteria
9. New class of antibiotics effective against drug-resistant bacteria discovered in fungi
10. Experimental TB drug effective against resistant and latent mycobacterium tuberculosis
11. Virginia Tech helping to develop higher quality, disease-resistant wheat varieties
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking ... Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity as ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... , June 23, 2016 ... market research report to its pharmaceuticals section with ... product details and much more. Complete ... across 151 pages, profiling 15 companies and supported ... at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The ...
Breaking Biology Technology: